EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction

BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumarakulasinghe, Nesaretnam Barr, Syn, Nicholas, Soon, Yu Yang, Asmat, Atasha, Zheng, Huili, Loy, En Yun, Pang, Brendan, Soo, Ross Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356756/
https://www.ncbi.nlm.nih.gov/pubmed/27907909
http://dx.doi.org/10.18632/oncotarget.13458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356756/
https://www.ncbi.nlm.nih.gov/pubmed/27907909
http://dx.doi.org/10.18632/oncotarget.13458

Ejemplares similares